Amicus Therapeutics (FOLD) EBITDA (2016 - 2025)
Historic EBITDA for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $34.3 million.
- Amicus Therapeutics' EBITDA rose 5822.06% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.8 million, marking a year-over-year increase of 52946.48%. This contributed to the annual value of $29.9 million for FY2024, which is 14125.89% up from last year.
- According to the latest figures from Q3 2025, Amicus Therapeutics' EBITDA is $34.3 million, which was up 5822.06% from -$9.5 million recorded in Q2 2025.
- Amicus Therapeutics' 5-year EBITDA high stood at $34.3 million for Q3 2025, and its period low was -$75.3 million during Q1 2022.
- For the 5-year period, Amicus Therapeutics' EBITDA averaged around -$23.9 million, with its median value being -$27.7 million (2024).
- Per our database at Business Quant, Amicus Therapeutics' EBITDA surged by 53258.4% in 2024 and then tumbled by 16329.93% in 2025.
- Over the past 5 years, Amicus Therapeutics' EBITDA (Quarter) stood at -$72.1 million in 2021, then soared by 41.33% to -$42.3 million in 2022, then surged by 91.28% to -$3.7 million in 2023, then soared by 532.58% to $16.0 million in 2024, then skyrocketed by 114.57% to $34.3 million in 2025.
- Its last three reported values are $34.3 million in Q3 2025, -$9.5 million for Q2 2025, and -$8.0 million during Q1 2025.